Atezolizumab-associated Dermatomyositis in Advanced Lung Small-cell Carcinoma

Dermatomyositis is a rare immune-related adverse event caused by immune checkpoint inhibitors. We herein report a 75-year-old Japanese man with small-cell lung carcinoma who developed dermatomyositis after the administration of atezolizumab. He developed rashes on day 13 and myalgia and motor weakne...

Full description

Saved in:
Bibliographic Details
Published in:Internal Medicine 2021, pp.6917-20
Main Authors: Yamaguchi, Yoshitaka, Aso, Mari, Nagasawa, Hikaru, Wada, Manabu
Format: Article
Language:English
Subjects:
anti-transcriptional intermediary factor 1-gammma antibody
atezolizumab
dermatomyositis
immune checkpoint inhibitor
immune-related adverse event
interleukin-6
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dermatomyositis is a rare immune-related adverse event caused by immune checkpoint inhibitors. We herein report a 75-year-old Japanese man with small-cell lung carcinoma who developed dermatomyositis after the administration of atezolizumab. He developed rashes on day 13 and myalgia and motor weakness on day 30 of the first administration of atezolizumab. Anti-transcriptional intermediary factor 1-gamma antibody was positive, and serum interleukin-6 levels were prominently elevated in the acute phase. Symptoms were improved by corticosteroid therapy. This is the first report of dermatomyositis associated with atezolizumab. Clinicians should be aware of the possibility of dermatomyositis after the administration of immune checkpoint inhibitors.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.6917-20